# SymBio Pharmaceuticals | 4582 |

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on our website at <a href="http://www.sharedresearch.ip">http://www.sharedresearch.ip</a> and various professional platforms. Our sponsored research reports provide an in-depth and informative view of the companies we cover, and contain the latest available information updated in a timely manner.



On August 5, 2015, SymBio Pharmaceuticals announced earnings results for Q2 FY12/15.

Quarterly Performance (cumulative)	FY12/14					FY12	2/15		FY'	12/15
(JPYmn)	Q1	O2	Q3	Q4	Q1	02	Q3	Q4	% of	
Sales	174	975	1,348	1,955		976			52.2	
YoY	-64.5%	20.3%	1.9%	27.6%		0.1%				122.1%
Gross profit	32	247	353	527	120	283				
YoY	-78.6%	34.1%	29.4%	65.6%	272.1%	14.3%				
GPM	18.6%	25.3%	26.2%	26.9%	29.5%	28.9%				
SG&A expenses	448	893	1,320	1,830	453	931				
YoY	-9.0%	-9.9%	-10.0%	-8.4%	1.1%	4.2%				
SG&A / sales	257.9%	91.6%	97.9%	93.6%	110.9%	95.3%				
Operating profit	-416	-646	-967	-1,303	-332	-648				-2,452
YoY	-	-	-	-	-	-				-
OPM	-	-	-	-	-	-				-
Recurring profit	-454	-713	-941	-1,110	-419	-674				-2,481
YoY	-	-	-	-	-	-				-
RPM	-	-	-	-	-	-				-
Net income	-455	-715	-944	-1,116	-420	-676				-2,485
YoY	-	-	-	-	-	-				-
NPM	-	-	-	-	-	-				_
Quarterly Performance		E140	744			E / 4 /	) / 4 E			
Qualitarity i cirorinanica		FY12	27 14			FY12	2/ 15			
(JPYmn)	Q1	FY 12 Q2	27 14 Q3	Q4	Q1	PY 12 Q2	27 15 Q3	Q4		
	Q1 174			Q4 607	Q1 408			Q4		
(JPYmn)	174	Q2	Q3 373		408	O2 568		Q4		
(JPYmn) Sales	174	O2 802	Q3 373	607	408	O2 568		Q4		
(JPYmn) Sales YoY	174 -64.5% 32	O2 802 149.1%	Q3 373 -27.3% 106	607 191.0%	408 135.0% 120	568 -29.2% 162		Q4		
(JPYmn) Sales YoY Gross profit	174 -64.5% 32	802 149.1% 215	Q3 373 -27.3% 106	607 191.0% 173	408 135.0% 120 272.1%	568 -29.2% 162		Q4		
(JPYmn) Sales YoY Gross profit YoY	174 -64.5% 32 -78.6%	802 149.1% 215 543.6%	373 -27.3% 106 19.8%	607 191.0% 173 286.1%	408 135.0% 120 272.1% 29.5%	568 -29.2% 162 -24.5%		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM	174 -64.5% 32 -78.6% 18.6% 448	802 149.1% 215 543.6% 26.8%	Q3 373 -27.3% 106 19.8% 28.5% 427	607 191.0% 173 286.1% 28.5%	408 135.0% 120 272.1% 29.5% 453	568 -29.2% 162 -24.5% 28.6%		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses	174 -64.5% 32 -78.6% 18.6% 448	02 802 149.1% 215 543.6% 26.8% 445 -10.8%	Q3 373 -27.3% 106 19.8% 28.5% 427	607 191.0% 173 286.1% 28.5% 510	408 135.0% 120 272.1% 29.5% 453 1.1%	568 -29.2% 162 -24.5% 28.6% 478		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY	174 -64.5% 32 -78.6% 18.6% 448 -9.0%	02 802 149.1% 215 543.6% 26.8% 445 -10.8%	03 373 -27.3% 106 19.8% 28.5% 427 -10.1%	607 191.0% 173 286.1% 28.5% 510 -4.3%	408 135.0% 120 272.1% 29.5% 453 1.1%	568 -29.2% 162 -24.5% 28.6% 478 7.3%		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9%	02 802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6%	Q3 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5%	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0%	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9%	568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1%		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales Operating profit YoY OPM	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9% -416	02 802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6%	Q3 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5% -320	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0%	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9%	02 568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1%		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales Operating profit YoY	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9% -416	802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6%	Q3 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5% -320	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0%	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9% -332	568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1% -316		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales Operating profit YoY OPM Recurring profit YoY	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9% -416	802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6% -231	Q3 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5% -320	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0% -337	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9% -332	568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1% -316		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales Operating profit YoY OPM Recurring profit	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9% -416454	802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6% -231 -	03 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5% -320 -	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0% -337	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9% -332 - -419	568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1% -316255		Q4		
(JPYmn) Sales YoY Gross profit YoY GPM SG&A expenses YoY SG&A / sales Operating profit YoY OPM Recurring profit YoY	174 -64.5% 32 -78.6% 18.6% 448 -9.0% 257.9% -416454	802 149.1% 215 543.6% 26.8% 445 -10.8% 55.6% -231 - - -259	Q3 373 -27.3% 106 19.8% 28.5% 427 -10.1% 114.5% -320 - -228	607 191.0% 173 286.1% 28.5% 510 -4.3% 84.0% -337	408 135.0% 120 272.1% 29.5% 453 1.1% 110.9% -332 - - -419	568 -29.2% 162 -24.5% 28.6% 478 7.3% 84.1% -316255		Q4		

Source: Company data

NPM

 $Figures\ may\ differ\ from\ company\ materials\ due\ to\ differences\ in\ rounding\ methods.$ 

Sales for Q2 FY12/15 totaled JPY976mn (+0.1% YoY) due to domestic and overseas sales of SyB L-0501 (Treakisym).

Though domestic sales of Treakisym increased 11.6% YoY, total sales of the product were up only 1.7% as overseas shipments were partially implemented in advance in the previous year.



SG&A expenses came to JPY931mn (+4.2% YoY), including research and development expenses worth JPY404mn (+9.0%), mainly for clinical trials for SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation), and other SG&A expenses worth JPY527mn (+0.7%).

As a result, operating loss totaled JPY648mn (Q2 FY12/14: loss of JPY646mn). The company also reported a recurring loss of JPY674mn (Q2 FY12/14: loss of JPY713mn), owing to non-operating expenses of JPY35mn, mainly from forex losses of JPY29mn. Net loss totaled JPY676mn (Q2 FY12/14: loss of JPY715mn)

#### **Domestic**

<u>Treakisym</u> (SyB L-0501; anticancer agent; generic name: bendamustine hydrochloride)

The company markets the anticancer agent Treakisym in Japan through its business partner, Eisai Co., Ltd. (TSE1: 4523) for the indications of refractory or relapsed low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Sales through Eisai increased as expected.

SymBio completed the phase II clinical trial of Treakisym for the first-line treatment of low-grade NHL and MCL in February 2014. The company is preparing the New Drug Application (NDA) for submission in Japan. The company will apply for approval as soon as the regulatory approval process for the application submitted by Astellas Pharma Europe Ltd. (a European subsidiary of Astellas Pharma Inc.; TSE1: 4503) is completed in the European Union.

The company completed patient enrollment for a phase II clinical trial for chronic lymphocytic leukemia (CLL) in October 2014. It plans to complete the trial and file an sNDA for marketing approval as soon as possible. Treakisym was designated as an orphan drug (drug for the treatment of rare diseases) for CLL in June 2012.

The company is still considering applying for approval for use of the drug for relapsed or refractory aggressive NHL.

Rigosertib (SyB L-1101 [IV]/SyB C-1101 [oral]; anticancer agent)

The company is conducting a domestic phase I clinical trial for the intravenous (IV) form of rigosertib in relapsed or refractory higher-risk myelodysplastic syndromes (MDS), a hematological malignancy. Patient enrollment was completed in January 2015.

Onconova Therapeutics, Inc., the U.S. licensor, plans to conduct a global Phase III trial for higher risk MDS patients who do not respond to treatment with hypomethylating agents (HMAs), the current standard of care ("Primary HMA Failure"), with clinical trial sites in more than ten countries worldwide. SymBio is considering its participation in the global clinical trial which is planned to begin in 2H of 2015 after completion of the domestic Phase I clinical trial.

As for SyB C-1101 (oral formulation, or Oral rigosertib), the company's domestic Phase I clinical trial for the target indication of higher risk MDS was completed in June, 2015. The company plans to continue clinical trials for the development of Oral rigosertib in combination with azacitidine for higher risk MDS, as well as for lower risk transfusiondependent MDS, and is considering its participation in the global clinical trial to be conducted by Onconova.

This note is the most recent addition to the full report.



## **About Shared Research Inc.**

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at http://www.sharedresearch.jp.

#### **Disclaimer**

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. Shared Research Inc. shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research Inc. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. SR Inc. officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

### Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research Inc. ("SR") under a contract with the company described in this report ("the Company"). Opinions and views presented are SR's where so stated. Such opinions and views attributed to the Company are interpretations made by SR. SR represents that if this report is deemed to include an opinion by SR that could influence investment decisions in the Company, such opinion may be in exchange for consideration or promise of consideration from the Company to SR.

#### **Contact Details**

#### Shared Research.inc

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

http://www.sharedresearch.jp Phone: +81 (0)3 5834-8787 Email: info@sharedresearch.jp

